Zhejiang Chunhe Pharmaceutical Technology

Zhejiang Chunhe Pharmaceutical Technology is a clinical-stage biopharmaceutical company headquartered in Hangzhou, China, specializing in the discovery and development of innovative small molecule therapeutics. The company's primary focus is on oncology, particularly targeting the ubiquitin-proteasome system to treat various cancers. Its lead candidate, CH-01, is a potent and selective USP7 inhibitor currently undergoing clinical evaluation for the treatment of advanced solid tumors. By leveraging its proprietary drug discovery platform, Zhejiang Chunhe aims to develop a robust pipeline of first-in-class and best-in-class medicines for patients with significant unmet medical needs. The company is led by a team of experienced scientists with a track record in global drug development.